Argireline at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Argireline (Acetyl Hexapeptide-3/8) is a synthetic hexapeptide developed by Lipotec (now part of Lubrizol) that mimics the N-terminal end of SNAP-25, a protein required for the SNARE complex that enables neurotransmitter release at the neuromuscular junction. By competing with SNAP-25, Argireline partially inhibits the vesicular acetylcholine release that causes facial muscle contractions - producing a milder, topical analog of botulinum toxin's mechanism without injections or toxin exposure.
Multiple clinical studies have demonstrated Argireline's ability to reduce the depth and appearance of expression lines (particularly periocular and forehead wrinkles) by 10-27% after 4-8 weeks of twice-daily application at concentrations of 5-10%. The effect is modest but measurable, reversible, and entirely safe for topical use.
Unlike botulinum toxin, Argireline's effect is concentration-dependent, gradual, and does not produce paralysis - it softens rather than eliminates expression lines. It is frequently combined with other cosmeceutical peptides (Matrixyl, Leuphasyl) in commercial formulations for synergistic wrinkle reduction.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.